At Taylor & Francis we have listened to feedback from our authors and funders and extended our open access option to cover more of our leading medical journals, including Current Medical Research and Opinion.
Current Medical Research and Opinion publishes research which supports primary care physicians in solving clinical problems and improving patient care. Using our Accelerated Publication option lets you coordinate publication with key events, combining this with open access gives your research the opportunity to have the widest possible impact. Explore some articles that have used both our Accelerated Publication and open access options in Current Medical Research and Opinion in 2019 below.
The role of sodium glucose cotransporter-2 (SGLT-2) inhibitors in heart failure and chronic kidney disease in type 2 diabetes is an open access article featured in our popular journal Current Medical Research and Opinion. Published in February 2019 it has already received over 2500 views within our platform as of July 2019.
This review discusses the significance of these comorbidities of T2D and current options for managing them, with a focus on sodium-glucose cotransporter-2 (SGLT-2) inhibitors. Based on a focused literature search of cardiovascular outcomes trials (CVOTs), this review assessed the effects of SGLT-2 inhibitors in individuals with T2D with or without established cardiovascular disease (CVD).
Treatment sequence network meta-analysis in Crohn’s disease: a methodological case study is an open access article featured in our popular journal Current Medical Research and Opinion. Published in February 2019 it has already received over 1000 views within our platform as of July 2019.
Several biologic therapies are available for the treatment of mild-to-moderate Crohn’s disease (CD). This network meta-analysis (NMA) aimed to assess the comparative efficacy of ustekinumab, adalimumab, vedolizumab and infliximab in the maintenance of clinical response and remission after 1 year of treatment. The NMA suggest that ustekinumab is associated with the highest likelihood of reaching response or remission at 1 year compared with placebo, adalimumab and vedolizumab. Results should be interpreted with caution because this is a novel methodology; however, the treatment sequence analysis may be the most methodologically sound analysis to derive estimates of comparative efficacy in CD in the absence of head-to-head evidence.
How much does it cost to publish Open Access?
The Article Publishing Charge for these journals is £3,250/$4,800/€4,000.
What licence can I publish under?
Our open access option allows the author to retain copyright under a CC-BY-NC-ND license.
Why publish Open Access?
- Immediate access to your article on publication, accessible by anyone, anywhere
- High visibility and discoverability via Taylor & Francis Online
- Input from, and dialog with, expert editors
- Rigorous peer review for every open access article
- Metrics (downloads, citations, and Altmetric data) for your article, so you can measure its impact
What are the benefits of Accelerated Publication?
- Control your publication schedule with concrete deadlines
- Stay ahead of the competition
- Coincide publication with key events
- Our Fast Track service is the fastest way to publish, with peer review completed in 1-2 weeks
- Support and guidance from our expert editors, every step of the way